B. Braun invest in BPMpathway

B. Braun, one of the world’s leading manufacturers of medical devices and pharmaceutical products and services, has announced a strategic investment in 270 Vision Limited, the UK-based developer of BPMpathway as part of their strategy of securing access to key future technology.

From left to right: Dr. Jens von Lackum (Aesculap AG), Hans Hux (B. Braun Medical Ltd.) and Martin Gossling (270 Vision Ltd.)

B. Braun is one of the world’s leading manufacturers of medical devices and pharmaceutical products and services, with 58,000 employees in 64 countries and a turnover of 6.13 billion Euro in 2015.

Product design and development company, 270 Vision, focuses on innovative wearable medical-grade sensors and advanced body data analysis technology for the professional sports and medical sectors.

BPMpathway forms a fundamental element of B. Braun’s TOTAL pathway concept for the field of Orthopaedic Joint Replacement, intended to accelerate and enhance patient recovery, whilst simultaneously reducing costs and enhancing efficiency.

To read the full press release,  click here.